Adamax

Adamax is a synthetic heptapeptide derived from Semax with an added adamantane group, and users take it off‑label for cognitive enhancement and neuroprotection. In the community the most common regimen is 500 µg per day, with doses reported from 125 µg up to 1.5 mg; a clinician source recommends 300 µg daily subcutaneously for 4–8 weeks. The only clear limitation is that it has no FDA‑approved indication, so all human use is off‑label or compounded, and injection‑site reactions have not emerged as a consistent issue.

Data last updated

ClinicalResearchDepthno dataClinicalResearchEfficacyno dataClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice3.73.21.0

Measured on 3 of 6 axes

Research Evidence

Evidence shape

Adamax currently lacks any published human clinical evidence or registered trials. Because there are no completed studies, there is no data to support its use for any specific indication or to establish a safety profile. The absence of peer-reviewed literature means that any claims regarding its efficacy or biological impact remain entirely speculative and unverified by clinical research.

Depthhow much
0 registered trials
Breadthhow many areas
0 indications mapped
Qualityhow rigorous
No completed trials

Anecdotal efficacy

Adamax side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

1
--
100 mg×10
$363.00
$3.63/mg
2
--
10 mg
$40.00
$4/mg
3
--
10 mg
$40.00
$4/mg
4
USA
40 mg
$189.99
$4.75/mg
5
--
10 mg
$50.00
$5/mg
6
GB
10 mg
$53.68
$5.37/mg

price offers can be sorted by column · 2 out-of-stock offers not shown

1-6 of 50

ADAMAX dosing & protocol

How ADAMAX is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
—
0
500 µg
1 mg
1.5 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
300 µg
typical
0
500 µg
1 mg
1.5 mg
across 1 dosed source · darker = more agree
By reported cadence
Daily300 µg · n=1
Frequency
daily
Route
subQ

The reported dosing regimen for ADAMAX in this tier consists of a 300‑microgram amount administered subcutaneously on a daily schedule.

1 source
Anecdotal
Community-reported real-world use · n = 14
Typical dose
500 µg50 µg – 1.5 mg
typical
0
500 µg
1 mg
1.5 mg
distribution of 17 reported doses · darker = more
Frequency
unspecified
Route
intranasal

Most reports give no set schedule, while a few note 300 mcg taken twice daily; amounts usually hover around 500 mcg but span 50 mcg to 1.5 mg.

14 sources